Mont. Mushroom: Molecular Identification, In vitro Anti-Diabetic, Anti-Obesity, and Cytotoxicity Assessment.

OBJECTIVES

Mushrooms are fungi with nutritional and health benefits. Mont., an edible fungus, has traditional usage and relevance in local therapy for managing metabolic diseases. In that view, this study aimed to evaluate the anti-obesity, anti-diabetic, and cytotoxic potential of the chloroform/methanol extract (CME) and aqueous extract (AE) of the mushroom.

MATERIALS AND METHODS

was identified using molecular biology tools. The CME and AE were obtained sequentially and, then, subjected to α-amylase, α-glucosidase, and lipase inhibitory enzyme assays as well as total phenolic content (TPC) and flavonoid content (TFC) estimations. The cytotoxic potential of extract fractions of was assessed using the brine shrimp lethality assay.

RESULTS

The molecular identification of the mushroom displayed that the internal transcribed spacer sequence was an equivalent match to that of with a high percentage similarity, and thus assigned a unique accession number (KT120043.1). The CME of had higher TPC, TFC, and α-glucosidase inhibitory activity than AE. Furthermore, AE of the mushroom showed a higher lipase inhibitory potential with an IC value of 22.28 ± 0.65 μg/mL than the CME, while that of the reference, orlistat was 2.28 ± 0.34 μg/mL. However, these extracts exhibited very low or no α-amylase inhibitory and cytotoxic activity at the tested concentrations.

CONCLUSION

This study reveals that CME of , rich in polyphenols and flavonoids, possesses considerable α-glucosidase and lipase inhibitory activities.